Amicus Therapeutics Inc to Discuss Top-Line Phase 3 Essence Study Results

13/9/2017 8:30

Conference Call Amicus Therapeutics Inc

Amicus Therapeutics Inc Conference call will be held on Sep 13, 2017. During the earnings conference call's session Amicus Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Amicus Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a global, late-stage, patient-focused biotechnology company engaged in the discovery and development of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. We own exclusive global rights to three clinical development programs that have the potential to address significant unmet needs, each with $500 million to $1 billion estimated global market opportunities. Our lead product candidate, migalastat HCl, is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, an LSD. The European Medicines Agency ("EMA") is currently reviewing our Marketing Authorisation Application ("MAA") for migalastat as the first potential personalized medicine for Fabry disease.    
Read more Conference Call

Amicus Therapeutics Inc (FOLD)

1 Cedar Brook Drive, Cranbury New Jersey 08512, United States